CRISPR Therapeutics AG
CRSP
Key stats
- Open
- 45.09
- Day high
- 45.09
- Day low
- 42.38
- Previous close
- 45.75
- Volume
- 2.49M
- VWAP
- 43.27
- 52-week high
- 63.45
- 52-week low
- 42.38
- Market cap
- 4.44B
- Shares out
- 97.00M
- Employees
- 393
- Listed
- 2016
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · ZUG · crisprtx.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 597
- Put open interest
- 1.1K
- Put/call
- 1.78
- At-the-money IV
- 101.4%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 51 put | 6.71 | Nov 12, 3:15 PM | 174 | 123 | 226.3% |
| 47 call | 0.01 | Nov 12, 2:36 PM | 107 | 110 | 186.4% |
| 46 put | 3.09 | Nov 12, 2:36 PM | 105 | 369 | 154.5% |
| 52 put | 9.20 | Nov 12, 3:29 PM | 73 | 32 | — |
| 42 put | 0.30 | Nov 12, 3:36 PM | 50 | 1 | 96.5% |
| 50 put | 5.60 | Nov 12, 3:15 PM | 50 | 39 | — |
Quarterly results
Massive · Nov 2, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $12.67M | $10.18M | $1.46M | $864.0K |
| Gross profit | $12.67M | $10.18M | $1.46M | $864.0K |
| Operating income | −$130.04M | −$117.27M | −$130.25M | −$154.76M |
| Net income | −$111.44M | −$91.15M | −$122.93M | −$130.61M |
| Diluted EPS | -1.15 | -0.94 | -1.28 | -1.37 |
| Operating cash flow | −$89.68M | −$83.50M | −$108.90M | −$92.55M |
| Assets | $2.56B | $2.65B | $2.73B | $2.27B |
| Liabilities | $908.34M | $904.22M | $911.26M | $343.43M |
| Equity | $1.65B | $1.75B | $1.81B | $1.92B |
Technicals
Massive · Nov 12, 2026- 50-day average52.38
- 200-day average52.58
- RSI (14 days)32.5
Short interest
Massive · Oct 30, 2026- Oct 30, 202617.19M shares · 13.1 days to cover
- Oct 15, 202616.44M shares · 10.2 days to cover
- Sep 30, 202618.68M shares · 9.6 days to cover
- Sep 15, 202619.07M shares · 16.5 days to cover
Related companies
MassiveNews coverage
No stories about CRISPR Therapeutics AG right now.